Women are less likely to be eligible for AD trials than men.

Based on commonly used inclusion criteria of clinical trials, women are less likely to be eligible for participation in AD drug trials than men. This discrepancy seems mainly related to lower MMSE at presentation and lack of caregiver presence. These results provide clues for design of trials to be alert for equal inclusion of women.